VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Gomella on Novel Prostate Cancer Immunotherapies

Leonard G. Gomella, MD
Published: Monday, Apr 18, 2011

Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses novel immunotherapies that are available for prostate cancer. The most exciting immunotherapy currently approved for prostate cancer is Provenge because of its very unique nature. Gomella believes that other immunotherapies, such as ipilimumab, may also move into the prostate cancer field.

View more videos of Leonard G. Gomella, MD.
Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses novel immunotherapies that are available for prostate cancer. The most exciting immunotherapy currently approved for prostate cancer is Provenge because of its very unique nature. Gomella believes that other immunotherapies, such as ipilimumab, may also move into the prostate cancer field.

View more videos of Leonard G. Gomella, MD.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field ForwardMay 30, 20181.5
Publication Bottom Border
Border Publication
x